GLSHQ (Gelesis Holdings) Notes Receivable: $0.00 Mil (As of Jun. 2023)


What is Gelesis Holdings Notes Receivable?

Gelesis Holdings GLSHQ -99.00% Notes Receivable is $0.00 Mil as of Jun. 2023.

Gelesis Holdings's Notes Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Gelesis Holdings Notes Receivable Related Terms

Gelesis Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Notes Receivable Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Notes Receivable
0.00 0.00

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gelesis Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Gelesis Holdings (GLSHQ) has a Notes Receivable of $0.00 Mil as of Jun. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Notes Receivable too high?
Gelesis Holdings' current Notes Receivable is $0.00 Mil.
How does Gelesis Holdings' Notes Receivable compare to RBSH and PPCB?
Gelesis Holdings' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Notes Receivable is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.